Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 1, 2014, Pages 23-31

  Morcos, Peter N ^a   Moreira, Sebastian A ^a   Navarro, Mercidita T ^b   Bech, Núria ^c   Quatkemeyer, Amanda ^a,d   Smith, Patrick F ^a,e   Brennan, Barbara J ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b GENENTECH INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d GILEAD SCIENCES   (United States)

^e D3 Medicine   (United States)

Author keywords

food; omeprazole; pharmacokinetics; ranitidine; ritonavir boosted danoprevir

Indexed keywords

DANOPREVIR; OMEPRAZOLE; RANITIDINE; RITONAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FATALITY; FAT INTAKE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

FOOD; OMEPRAZOLE; PHARMACOKINETICS; RANITIDINE; RITONAVIR-BOOSTED DANOPREVIR;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; LACTAMS; MALE; MEALS; NEUROPEPTIDES; OMEPRAZOLE; RANITIDINE; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 84891004605     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12151     Document Type: Article

References (37)

1. Gane EJ, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 972-979.
2. Rajagopalan R, et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 2009; 48: 2559-2568.
3. Seiwert SD, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-4441.
4. Imhof I, Simmonds P,. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53: 1090-1099.
5. Reddy M, et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics. Results of computer-based simulations and a clinical drug-drug interaction study. Clin Pharmacokinet 2012; 51: 457-465.
6. Everson G, et al. High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology 2012; 56 (Suppl. 1): 552A.
7. Merck & Co. I. VICTRELIS (boceprevir) prescribing information 2012 [revised Sept 2013]. Available from: http://www.merck.com/product/usa/pi- circulars/v/victrelis/victrelis-pi.pdf
8. Van Heeswijk R, et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir [abstract 19]. Rev Antivir Ther Infect Dis 2011; 6: 21.
9. Vertex Pharmaceuticals Ltd. INCIVEK (telaprevir) prescribing information [revised April 2013 ]. Available from: http://pi.vrtx.com/files/uspi-telaprevir. pdf
10. Bradford B, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects. Hepatology 2008; 48 (Suppl. 1): 1146A.
11. Luber AD,. Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes. AIDS Read 2005; 15: 698-700.
12. Khanlou H, Farthing C,. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr 2005; 39: 503-504.
13. Klein CE, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol 2008; 48: 553-562.
14. Blume H, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29: 769-784.
15. Gerson LB, Triadafilopoulos G,. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13: 611-616.
16. Louie KS, et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012; 12: 86-96.
17. Sanyal C, et al. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. Can J Hosp Pharm 2011; 64: 131-140.
18. Luber AD, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007; 8: 457-464.
19. Winston A, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006; 20: 1401-1406.
20. Reddy MB, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos 2011; 32: 261-275.
21. Food and Drug Administration. Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2002 [cited 22 Aug 2012]. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf.
22. Schmidt LE, Dalhoff K,. Food-drug interactions. Drugs 2002; 62: 1481-1502.
23. Winstanley PA, Orme ML,. The effects of food on drug bioavailability. Br J Clin Pharmacol 1989; 28: 621-628.
24. Martinez MN, Amidon GL,. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42: 620-643.
25. Halfon P, Locarnini S,. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
26. Sarrazin C, et al,. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
27. Rubino C, et al. Pharmacodynamic (PK-PD) relationships for ITMN-191 in a phase 1 Multiple Ascending Dose (MAD) trial in patients with genotype 1 chronic hepatitis C infection. Hepatology 2008; 48 (Suppl. 1): 1140A.
28. Ng J, et al. The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects. J Intl AIDS Soc 2008; 11 (Suppl. 1): P247.
29. Abbott Laboratories. Abbott Laboratories. Ritonavir prescribing information 2012 [revised Jan 2013]. Available from: http://www.rxabbvie.com/ pdf/norvirtab-pi.pdf
30. Wilder-Smith CH, et al,. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35: 976-983.
31. Winthrop Pharmaceuticals UK Ltd. Omeprazole-summary of product characteristics [updated 29 Aug 2012]. Available from: http://www.medicines.org. uk/emc/medicine/24226/SPC
32. GlaxoSmithKline. Ranitidine-summary of product characteristics [updated 4 Jul 2013]. Available from: http://www.medicines.org.uk/emc/medicine/10635/SPC
33. 2-receptor antagonists. Clin Pharmacol Ther 1999; 65: 369-376.
34. Hatlebakk JG, Berstad A,. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
35. Betlach CJ, et al. The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet. Pharm Res 1991; 8: 1516-1519.
36. Ko JW, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.
37. Haznedar J, et al. Effects of multiple doses of ketoconazole on the pharmacokinetics of R7227 (ITMN-191), a highly potent and selective inhibitor of the HCV NS3/4a protease. Presented at the 4th Annual Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2009; Boston, MA.